<DOC>
	<DOC>NCT02800954</DOC>
	<brief_summary>The Primary objective of this study is to compare serum levels of Macrophage-Colony Stimulating Factor (M-CSF) in a population of patients with multiple myeloma (MM), in a population of patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and in a control population.</brief_summary>
	<brief_title>Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>For the multiple myeloma group confirmed diagnosis of de novo multiple myeloma according to the International Myeloma Working Group criteria bisphosphonate therapy for more than 60 days, signature of the informed consent form, patients over the age of 18 years. For the monoclonal gammopathy of undetermined significance (MGUS) group confirmed diagnosis of MGUS according to the International Myeloma Working Group criteria signature of the informed consent form, patients over the age of 18 years. For the healthy control group signature of the informed consent form, subjects over the age of 18 years. patients with thyroid or parathyroid disease, osteomalacia, rheumatoid arthritis, Paget's disease, osteoporosis, bisphosphonate therapy for less than 60 days, absence of informed consent, patients under the age of 18 years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>bone lesions</keyword>
	<keyword>Macrophage-Colony Stimulating Factor</keyword>
</DOC>